Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/34300
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2023-10-12T06:26:05Z-
dc.date.available2023-10-12T06:26:05Z-
dc.date.issued2016-09-02-
dc.identifier.citationAyar, Y. vd. (2016). "Primary glomerulonephritis: A single-center retrospective experience". Acta Medica Mediterranea, 32(5), 1723-1727.en_US
dc.identifier.issn0393-6384-
dc.identifier.issn2283-9720-
dc.identifier.urihttp://hdl.handle.net/11452/34300-
dc.description.abstractAim: Primary glomerular diseases (PGD) are seen frequently. Age, gender, geographical characteristics and genetic affect the distribution of the disease. Despite the treatment, a part of the disease may progress to end-stage renal disease. We evaluated the PGD patients and retrospectively regarding to their clinical and histopathological characteristics.Materials and methods: In this study PGD patients, who have had renal biopsy between 1st January 2009 and 31st December 2014 were evaluated. Clinical and laboratory characteristics, response of the treatment, biopsy evidences, and the risk factors associated with mortality were analyzed. We also compared the cases of primary glomerulonephritis retrospectively. The mean value of the follow-up periods was 22 months (range: 8 - 76 months).Results: The median age was 42 years (18 - 80) in 264 patients. When five groups were compared, there was statistically important difference between the groups (p < 0.001). The distributions of PGD subgroups were 40.5% for membranous glomerulonephritis (MGN), 20.4% for IgA nephropathy (IgAN), 25.7% for focal segmental glomerulosclerosis (FSGS), 7.9% for minimal change disease (MCD) and 5.3% for membranoproliferative glomerulonephritis (MPGN). The distrubition of gender was not significantly in the five PGD groups (p=0.269). Nephrotic syndrome was the most biopsy indication in MGN patients (76.6%). Nephritic syndrome was more seen in immunoglobulin A nephropathy (IgAN) patients (63%). Chronic kidney disease was more detected in focal segmental glomerulosclerosis (FSGS) patients as biopsy indication (p<0.001). Minimal change disease (MCD) and IgAN patients were more received with steroid treatment (85.7% and 55.5% respectively). Cyclophosphamide was more received in MGN patients. Serum IgG levels were more higher in FSGS and IgAN patients (p<0.001). Partial remission was more seen in MCD patients. Complete remission was more detected in MGN and FSGS patients. 29.1% of IgAN patients were not received treatment response. Six year renal survival rates were 84.1% (MGN), 87.1% (IgAN), 95.3% (MCD), 64.3% (MPGN) and 76.5% (FSGS) respectively.Conclusion: Biopsy maintains its diagnostic importance in glomerular diseases. Renal functions at diagnosis are important in response to treatment. Early diagnosis, follow-up and appropriate immunosuppressive medications affect mortality and clinical progress in PGD.en_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGeneral & internal medicineen_US
dc.subjectPrimary glomerular diseaseen_US
dc.subjectProteinuriaen_US
dc.subjectRenal biopsyen_US
dc.subjectPrognosisen_US
dc.titlePrimary glomerulonephritis: A single-center retrospective experienceen_US
dc.typeArticleen_US
dc.identifier.wos000390172000027tr_TR
dc.identifier.scopus2-s2.0-84992193815tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Nefroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0342-9692tr_TR
dc.contributor.orcid0000-0002-7846-0870tr_TR
dc.contributor.orcid0000-0001-5478-3192tr_TR
dc.contributor.orcid0000-0003-4607-9220tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.contributor.orcid0000-0003-4607-9220tr_TR
dc.contributor.orcid0000-0003-4607-9220tr_TR
dc.identifier.startpage1723tr_TR
dc.identifier.endpage1727tr_TR
dc.identifier.volume32tr_TR
dc.identifier.issue5tr_TR
dc.relation.journalActa Medica Mediterraneaen_US
dc.contributor.buuauthorAyar, Yavuz-
dc.contributor.buuauthorErsoy, Alparslan-
dc.contributor.buuauthorCan, Fatma Ezgi-
dc.contributor.buuauthorGüllülü, Mustafa-
dc.contributor.buuauthorBayrakcı, İsmail-
dc.contributor.buuauthorDemirayak, Dilay-
dc.contributor.buuauthorDüger, Hakan-
dc.contributor.buuauthorOcak, Tuğba-
dc.contributor.buuauthorOruç, Ayşegül-
dc.contributor.buuauthorYıldız, Abdülmecit-
dc.contributor.buuauthorKorkut, Bayram-
dc.contributor.buuauthorŞahin, Ahmet Bilgehan-
dc.contributor.buuauthorCamcı, Nihal Yücel-
dc.contributor.buuauthorVuruşkan, Berna Aytaç-
dc.contributor.researcheridAAH-4002-2021tr_TR
dc.contributor.researcheridAAM-4927-2020tr_TR
dc.contributor.researcheridGPK-6118-2022tr_TR
dc.contributor.researcheridO-9948-2015tr_TR
dc.contributor.researcheridAAH-9746-2021tr_TR
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.researcheridGSE-0029-2022tr_TR
dc.contributor.researcheridGDL-7686-2022tr_TR
dc.contributor.researcheridCTG-8811-2022tr_TR
dc.contributor.researcheridELN-3407-2022tr_TR
dc.contributor.researcheridEQO-1344-2022tr_TR
dc.contributor.researcheridFPM-3131-2022tr_TR
dc.contributor.researcheridHIG-9032-2022tr_TR
dc.contributor.researcheridFFH-4157-2022tr_TR
dc.contributor.researcheridCHG-6819-2022tr_TR
dc.subject.wosMedicine, general & internalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid55860143300tr_TR
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid56689608500tr_TR
dc.contributor.scopusid6602684544tr_TR
dc.contributor.scopusid57191504355tr_TR
dc.contributor.scopusid57191498699tr_TR
dc.contributor.scopusid58423722100tr_TR
dc.contributor.scopusid57191501503tr_TR
dc.contributor.scopusid55133912100tr_TR
dc.contributor.scopusid56256977500tr_TR
dc.contributor.scopusid57191504817tr_TR
dc.contributor.scopusid57188809248tr_TR
dc.contributor.scopusid57191628115tr_TR
dc.contributor.scopusid56527372000tr_TR
dc.subject.scopusGlomerulonephritis; Lupus Erythematosus Nephritis; Immunoglobulin A Nephropathyen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAlbumin blood levelen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCholesterol blood levelen_US
dc.subject.emtreeClinical evaluationen_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFocal glomerulosclerosisen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeGlomerulonephritisen_US
dc.subject.emtreeHemodialysisen_US
dc.subject.emtreeHistopathologyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeImmunoglobulin A nephropathyen_US
dc.subject.emtreeImmunoglobulin blood levelen_US
dc.subject.emtreeKidney biopsyen_US
dc.subject.emtreeKidney transplantationen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMembranoproliferative glomerulonephritisen_US
dc.subject.emtreeMembranous glomerulonephritisen_US
dc.subject.emtreeMinimal change diseaseen_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreeNephrotic syndromeen_US
dc.subject.emtreePrimary glomerulonephritisen_US
dc.subject.emtreePrognosisen_US
dc.subject.emtreeProtein urine levelen_US
dc.subject.emtreeProteinuriaen_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeSex ratioen_US
dc.subject.emtreeStatistical analysisen_US
dc.subject.emtreeStatistical distributionen_US
dc.subject.emtreeSurvival rateen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeTriacylglycerol blood levelen_US
dc.subject.emtreeAlbuminen_US
dc.subject.emtreeAngiotensin receptor antagonisten_US
dc.subject.emtreeAzathioprineen_US
dc.subject.emtreeCholesterolen_US
dc.subject.emtreeCyclophosphamideen_US
dc.subject.emtreeCyclosporin Aen_US
dc.subject.emtreeDipeptidyl carboxypeptidase inhibitoren_US
dc.subject.emtreeImmunoglobulin Gen_US
dc.subject.emtreeLow density lipoprotein cholesterolen_US
dc.subject.emtreeMycophenolate mofetilen_US
dc.subject.emtreeSteroiden_US
dc.subject.emtreeTriacylglycerolen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.